Optimization and antiviral analysis of peptide ligands for the HIV-1 packaging signal PSI by Dietz, Julia et al.
BioMed  Central
Page 1 of 1
(page number not for citation purposes)
Retrovirology
Open Access Oral presentations
Optimization and antiviral analysis of peptide ligands for the HIV-1 
packaging signal PSI
Julia Dietz1, Anette Pustowka1, Ajit Kaur2, Joachim Koch3, Sarah Mensch2, 
Stefan Stein1, Manuel Grez1, Gilles Divita4, Yves Mély5, Harald Schwalbe2 
and Ursula Dietrich*1
Address: 1Georg-Speyer-Haus, Frankfurt/Main, Germany, 2Organic Chemistry, J. W. Goethe University, Frankfurt, Germany, 3Biochemistry, J. W. 
Goethe University, Frankfurt, Germany, 4CRBM-CNRS, Montpellier, France and 5CNRS, Université Louis Pasteur, Strasbourg, France
* Corresponding author    
Background
We selected peptide ligands for the HIV-1 packaging sig-
nal PSI by screening phage displayed peptide libraries.
Peptide ligands were optimized by screening spot synthe-
sis peptide membranes. The aim of this study is the func-
tional characterization of these peptide ligands with
respect to inhibition of HIV-1 replication.
Methods
Phage displayed peptide libraries were screened with PSI-
RNA structures. The Trp-rich peptide motifs were opti-
mized for specific binding on spot synthesis peptide
membranes. The best binding peptide was expressed
intracellularly in fusion with RFP or linked to a protein
transduction domain (PTD) for intracellular delivery. The
effects on virion production were analyzed using pseudo-
typed lentiviral particles.
Results
After positive and negative selection rounds, phages bind-
ing specifically to PSI-RNA were identified by ELISA. Pep-
tide inserts contained conserved motifs of aromatic amino
acids known to be implicated in binding of PSI-RNA by
the natural Gag ligand. The filter assay identified
HKWPWW as the best binding ligand for PSI-RNA, which
is delivered into several cell lines by addition of a PTD.
Compared to a control peptide, the HKWPWW peptide
inhibited HIV-1 replication as deduced from reduced tit-
ers of culture supernatants. As HKWPWW also binds to
the TAR-RNA like the natural nucleocapsid PSI-RNA lig-
and, the effect on Tat-TAR inhibition will also be ana-
lyzed. Currently T-cell lines are established which stably
express HKWPWW as well as a control peptide, which will
be infected with HIV-1 to monitor the ability of
HKWPWW to inhibit wild type HIV-1 replication.
Conclusion
The selection of a peptide ligand for PSI-RNA able to
inhibit HIV-1 replication proves the suitability of the
phage display technology for the selection of peptides
binding to RNA-structures. This enables the indentifica-
tion of peptides serving as leads to interfere with addi-
tional targets in the HIV-1 replication cycle.
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